Rational use of new and existing disease-modifying agents in rheumatoid arthritis

Annals of Internal Medicine

Volumn 134, Issue 8, 2001, Pages 695-706

  Kremer, J M ^a  

^a Center for Rheumatology LLP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOSPORIN; ETANERCEPT; FOLIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE;

ARTHROPLASTY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0035901624     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-8-200104170-00013     Document Type: Review

References (87)

1. The costs of rheumatoid arthritis: An international long-term view
2. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients
3. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis
4. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: A 20 year study
5. Work disability in rheumatoid arthritis 10 years after the diagnosis
6. Work disability in rheumatoid arthritis: Effects of disease, social, and work factors
7. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years
8. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease
9. Radiographic changes in early rheumatoid disease
10. Early radiographic joint space narrowing and erosion and later malalignment in rheumatoid arthritis: A longitudinal analysis
11. Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression
12. Taking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbidity
13. Efficacy of low-dose methotrexate in rheumatoid arthritis
14. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial
15. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Followup after a mean of 13.3 years
16. Longterm prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy
17. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables
18. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: A multicenter study with literature review
19. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology
20. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study
21. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis
22. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial
23. Is methotrexate oncogenic in patients with rheumatoid arthritis?
24. Methotrexate
25. Methotrexate: Use for the treatment of rheumatoid arthritis and other rheumatic disorders
26. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update
27. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months
28. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis
29. The C6777 mutation in the MTHFR-gene: Association with efficacy and toxicity of methotrexate with or without folate supplementation in the treatment of rheumatoid arthritis patients
30. 5′10′ methylentetrahydrofolate reductase gene expression in rheumatoid arthritis patients receiving methotrexate therapy
31. Molecular therapeutics. Methotrexate and its mechanism of action
32. Does aggressive therapy of rheumatoid arthritis affect outcome?
33. Long-term outcome of treating rheumatoid arthritis: Results after 20 years
34. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
35. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis
36. Remodelling the pyramid: The therapeutic target of rheumatoid arthritis
37. Early rheumatoid arthritis: Time to aim for remission?
38. Rheumatoid arthritis: Treat now, not later!
39. Combination DMARD therapy for rheumatoid arthritis: Apparent universal acceptance
40. Use of second lire "disease modifying" antirheumatic drugs (DMARDs) within 5 months of disease onset by 64% of 750 rheumatoid arthritis patients under care of 142 US rheumatologists: An inception cohort study
41. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study
42. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis
43. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
44. An international consensus report. The use of cyclosporin A in rheumatoid arthritis
45. Long-term safety of cyclosporine/sand-immune alone and in combinations with methotrexate in the treatment of active rheumatoid arthritis: Analysis of open label extension studies
46. Treatment of RA patients with methotrexate plus cyclosporin A leads to elevation of plasma methotrexate levels and decrease of 7 hydroxymethotrexate levels
47. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
48. Combination DMARD therapy with methotrexate, sulfasalazine, hydroxychloroquine in rheumatoid arthritis: Continued efficacy with minimal toxicity at 5 years
49. Methotrexate (M)-hydroxychloroquite (H)-sulfasalazine (S) versus M-H or M-S for rheumatoid arthritis: Results of a double-blind study
50. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study
51. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group
52. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
53. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
54. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis
55. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
56. A phase III, randomized, double-blind study of leflunomide versus methotrexate in rheumatoid arthritis
57. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
58. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
59. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
60. 54-Week clinical and radiographic results from the attract trial: A phase III study of infliximab (Remicade) in patients with active RA despite methotrexate
61. Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice
62. Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis
63. How does leflunomide modulate the immune response in rheumatoid arthritis?
64. Mechanism of action for leflunomide in rheumatoid arthritis
65. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression
66. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production
67. Leflunomide
68. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group
69. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients
70. The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: A double-blind placebo controlled study
71. Cytokines in autoimmunity
72. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients With rheumatoid arthritis
73. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells
74. The effect of recombinant tumor necrosis factor-alpha on superoxide and metalloproteinase production by synovial cells and chondrocytes
75. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha
76. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity
77. Isolation and characterization of a tumor necrosis factor binding protein from urine
78. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group
79. Etanercept in addition to methotrexate in rheumatoid arthritis: Long-term observations
80. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia
81. Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients
82. Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis
83. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis
84. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
85. Demyelination diagnosed during etanercept therapy